Latest News and Press Releases
Want to stay updated on the latest news?
-
VIRGINIA CITY, Nev., March 24, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) ("Comstock" or the "Company"), a leader in converting under-utilized natural resources into renewable energy...
-
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
-
Profitable Growth Initiatives Lead to Sequential Quarterly Improvement Neal Cohane Appointed Interim Chief Executive Officer NORWALK, Conn., March 24, 2026 (GLOBE NEWSWIRE) -- Reed’s, Inc. (NYSE...
-
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash...
-
DETROIT, March 24, 2026 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse”) a North American OEM and provider of all-electric trucks, shuttles and buses, plans to conduct a...
-
Fourth quarter and full year results reflect temporary planned scale back in wholesale production At year-end was back to fully planted with legacy greenhouses and the most overall acreage planted in...
-
VIRGINIA CITY, Nev., March 24, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced its full year 2025 results, 2025 summary achievements, and...
-
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury...
-
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
-
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201...